Data Asset · Updated Monthly
GLP-1 Price Index
Last verified Oct 25, 2026 · October 2026 edition
This is the dataset behind the GLP-1 Cost Tracker: the published monthly list price for every legal way to get Wegovy, Zepbound, and Foundayo — savings card, self-pay, patient assistance, Medicare, and Medicaid — each figure carrying an as-of date and a link to its primary source. No other site maintains this. We take no money from providers or manufacturers — members fund the research.
Master Table
Every legal channel, priced and dated
Each row is one access channel. "Monthly list price" is the figure published by the source on its as-of date; ranges reflect dose or refill-timing tiers noted in the eligibility column. A price of "Plan-specific — no single published price" means the channel has no single posted number because the cost depends on your plan.
| Drug | Channel | Monthly list price | As-of date | Source URL | Eligibility / notes | Order confirmation required | Order confirmation source URL | Auto-refill default | Auto-refill source URL | Cancellation method | Cancellation source URL | FDA warning letter | FDA warning letter date | FDA warning letter URL | Billing verified as-of |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide (Wegovy) | Wegovy savings card (commercial insurance) | $25/mo | Oct 25, 2026 | Source ↗ | Eligible commercial insurance only — Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month. Applies to both the Wegovy pen and the Wegovy pill. | ||||||||||
| Tirzepatide (Zepbound) | Zepbound savings card (commercial insurance) | $25/mo | Oct 25, 2026 | Source ↗ | Commercial insurance only; applies to the single-dose pen (not the KwikPen or vials). Savings are capped at $100/month and $1,300/year, and the card expires 12/31/2026. | ||||||||||
| Foundayo (oral orforglipron) | Foundayo savings card (commercial insurance) | $25/mo | Oct 25, 2026 | Source ↗ | Commercial insurance that covers Foundayo only; Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month and $1,000/year, and the card expires 12/31/2026. | ||||||||||
| Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | $349/mo (0.25–2.4 mg pen) | Oct 25, 2026 | Source ↗ | New patients pay $199/mo for the first 2 months (0.25 mg or 0.5 mg) through December 31, 2026, then $349/mo. The Wegovy HD 7.2 mg pen is $399/mo. The Wegovy pill is $149/mo (1.5 mg), $199/mo (4 mg), or $299/mo (9 mg and 25 mg). | ||||||||||
| Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | $299–$449/mo | Oct 25, 2026 | Source ↗ | Priced by dose, whether you get one KwikPen or four single-dose vials a month: $299 (2.5 mg), $399 (5 mg), or $449 (7.5 mg to 15 mg). The $449 price requires a refill within 45 days of your last delivery; otherwise you pay $499 (7.5 mg) or $699 (10 mg to 15 mg). Needles and other injection supplies are extra. | ||||||||||
| Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | $149–$299/mo | Oct 25, 2026 | Source ↗ | $149/mo for 0.8 mg and 2.5 mg, $199/mo for 5.5 mg, and $299/mo for 9 mg and up. The 2.5 mg and 5.5 mg prices are temporary through December 31, 2026 (regular $199 and $299). For 14.5 mg and 17.2 mg, the $299 price requires a refill within 45 days of your last delivery; otherwise it is $349/mo. | ||||||||||
| Semaglutide (Wegovy) | Novo Nordisk Patient Assistance Program (Wegovy not included) | Not available for Wegovy | Oct 25, 2026 | Source ↗ | Novo Nordisk's 2026 PAP product list does not include Wegovy. The only drug in its GLP-1 category is Ozempic, which is approved for type 2 diabetes, and only for uninsured patients with household income at or below 200% of the federal poverty level. For uninsured Wegovy patients, the self-pay prices above are the lowest verified option. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Medicare GLP-1 Bridge | $50/mo | Oct 25, 2026 | Source ↗ | Covers the Wegovy pen and pill, Foundayo, and the Zepbound KwikPen only (not Zepbound vials or single-dose pens; pen needles are not covered). You need a standalone Part D plan or a Medicare Advantage HMO or PPO plan with drug coverage, plus a prior authorization showing you meet CMS's BMI criteria. Not for people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (MASH), or anyone getting a GLP-1 through Part D. Your Part D deductible does not apply, the $50 does not count toward your out-of-pocket cap, and Extra Help and coupons cannot lower it. Runs July 1, 2026 to December 31, 2027. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Standard Part D (outside the Bridge) | Plan-specific — no single published price | Oct 25, 2026 | Source ↗ | If you qualify for one of these medical indications, this is not weight-loss coverage and different plan rules apply. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | State Medicaid coverage | $0–low copay | Oct 25, 2026 | Source ↗ | Coverage is state-by-state and, where offered, requires prior authorization and BMI criteria. KFF counted 13 state programs covering GLP-1s for weight loss in January 2026. Michigan narrowed its coverage on January 1, 2026. Since then, Massachusetts (July 1) and Rhode Island (October 1) have ended weight-loss coverage, and Utah limited its pilot approvals to June 30, 2026. |
Billing Practices
How each channel handles orders, refills, and cancellations
How to read this table. Each value below is a dated, sourced statement of fact — not a grade, score, ranking, or safety rating. We report what a channel's own published pages say and nothing more.
- Order confirmation, auto-refill default, and cancellation method were checked only against each vendor's published terms of service, refund policy, and FAQ pages. We did not create accounts, enter payment details, or place orders. Where the published terms are silent, the value is “Not verified” — never inferred or guessed.
- FDA warning letter was checked against the FDA warning-letter database at fda.gov/safety/warning-letters (searched for “telehealth” and each company name). A warning letter records the FDA's alleged violations; it is not a court finding or a determination of guilt, and a company may have already corrected the claims at issue. “No public letter found” means no letter naming that company was visible in the database on the date checked — not that one could never exist.
- Every non-“Not verified” value links to the exact page it came from. All billing fields were last verified on Aug 9, 2026.
Verified vs. “Not verified” across 10 channels — Order confirmation: 3/10 · Auto-refill default: 0/10 · Cancellation method: 0/10 · FDA warning letter (“Yes”): 0/10.
| Drug | Channel | Order confirmation required | Auto-refill default | Cancellation method | FDA warning letter |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) | Wegovy savings card (commercial insurance) | Not verified | Not verified | Not verified | No public letter found |
| Tirzepatide (Zepbound) | Zepbound savings card (commercial insurance) | Not verified | Not verified | Not verified | No public letter found |
| Foundayo (oral orforglipron) | Foundayo savings card (commercial insurance) | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy) | Novo Nordisk Patient Assistance Program (Wegovy not included) | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Medicare GLP-1 Bridge | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Standard Part D (outside the Bridge) | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | State Medicaid coverage | Not verified | Not verified | Not verified | No public letter found |
What Changed This Month
October 2026: what changed in this update
We re-verified every channel at its primary source on Oct 25, 2026. One correction changes a cheapest path: Novo Nordisk’s patient assistance program does not include Wegovy. Billing details (order confirmation, auto-refill, cancellation) were last checked Aug 9, 2026. Each change below has one plain-English line on what it means for patients.
| Item | Old | New | What it means for patients |
|---|---|---|---|
| Novo Nordisk patient assistance (Wegovy) | $0 | Not available for Wegovy | Correction. Novo Nordisk's 2026 patient assistance list includes Ozempic (for uninsured patients with low income) but not Wegovy. For uninsured Wegovy buyers, self-pay ($199/mo for the first 2 months, then $349/mo) is the lowest verified price. |
| Foundayo savings card (commercial insurance) | No single published price | $25/mo | Lilly now lists a Foundayo savings card for commercial plans that cover it: as little as $25, capped at $100/month and $1,000/year, expiring December 31, 2026. Government plans are excluded. |
| Foundayo self-pay, 2.5 mg and 5.5 mg | $199 and $299/mo | $149 and $199/mo through Dec 31, 2026 | Temporary Lilly prices for two doses. The overall Foundayo self-pay range is still $149 to $299/mo, with the top doses at $349/mo if you miss the 45-day refill window. |
| Zepbound self-pay price ladder | Vials $299; KwikPens $399–$449 | $299, $399 or $449 by dose | Correction to how we described it. The price depends on the dose, not on vials versus KwikPen. The range did not move. Missing the 45-day refill window raises the higher doses to $499 or $699. |
| Medicare GLP-1 Bridge | $50/mo | $50/mo (no change) | Price unchanged; it runs through December 31, 2027. We added the prior authorization and BMI rules. CMS says the BALANCE Model will not launch in Medicare Part D in 2027. |
| State Medicaid (weight-loss coverage) | 13 states (KFF, Jan 2026) | MA and RI ended; MI narrowed; UT unconfirmed | Michigan limited weight-loss coverage to severe obesity on January 1. Massachusetts ended it on July 1 and Rhode Island on October 1, 2026. Utah's prior-authorization form limits pilot approvals to June 30, 2026, so we now list Utah as unconfirmed. We also added North Carolina, which covers it. |
| All other tracked prices | July 31 figures | No change | Both $25/mo savings cards (Wegovy and Zepbound), Wegovy self-pay ($349/mo), Zepbound self-pay ($299 to $449/mo), and the $50/mo Medicare Bridge held steady. |
Methodology
How this index is built and verified
Every price in this index is a list price published by a primary source: the manufacturer’s own self-pay and savings pages (Novo Nordisk / NovoCare and Eli Lilly / LillyDirect), each program’s official terms, and government coverage pages (CMS for the Medicare GLP-1 Bridge, and KFF’s state Medicaid tracking). We do not use aggregator estimates, discount-card screenshots, or unverifiable figures. "Verified" means one of us opened the source on the as-of date shown and confirmed the number against it; any figure we cannot confirm is flagged and left out rather than guessed. We re-check every source at least monthly, and sooner when a program announces a change. These are list prices — your actual out-of-pocket cost can differ with insurance, eligibility, dose, and refill timing, all noted in the eligibility column.
We take no money from providers, pharmacies, or manufacturers, and this page carries zero affiliate links. Members of the GLP-1 Cost Tracker fund the research.
Cite this page
- Publisher
- GLP-1 Answers
- Title
- GLP-1 Price Index
- Last verified
- Oct 25, 2026
GLP-1 Answers. GLP-1 Price Index. Last verified Oct 25, 2026. https://www.glp1answers.org/data/glp1-price-index
Download & formats
The full dataset is available as a CSV generated from the same source data as the table above — columns match exactly.
Download glp1-price-index.csv